Turn Therapeutics Inc.: Business Overview, Financials & Competitive Analysis
Turn Therapeutics Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). High-risk early-stage biotech with meaningful clinical validation catalysts ahead; success hinges on GX-03 efficacy data and near-term achievement of clinical/commercial milestones. Turn exhibits promise as an early-stage biotech with an innovative delivery platform and clear clinical pathway (GX-03 Phase 2 data expected H1 2026), but faces significant risk as.
What is Turn Therapeutics Inc.'s industry? Turn Therapeutics Inc. (turntherapeutics.com) operates in Clinical-stage Biotechnology - Dermatology/Immunology. AskCyborg classifies Turn Therapeutics Inc. under Clinical-stage Biotechnology - Dermatology/Immunology in its company registry.
Turn Therapeutics is a clinical-stage biotechnology company developing precision therapeutics using its proprietary PermaFusion delivery platform to enable localized drug administration. The company is advancing first...
Cyborg Score thesis
High-risk early-stage biotech with meaningful clinical validation catalysts ahead; success hinges on GX-03 efficacy data and...
Read the full analyst-debate transcript →Get the Latest Turn Therapeutics Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTurn Therapeutics Inc. Overview
Pro stress-test →Turn Therapeutics is a clinical-stage biotechnology company developing precision therapeutics using its proprietary PermaFusion delivery platform to enable localized drug administration. The company is advancing first-in-class treatments targeting dermatologic inflammation, wound care, and infectious disease, with its lead program GX-03 expected to generate interim data in H1 2026.
Strategic Profile
Pro stress-test →Turn differentiates through its oil-based delivery technology that enables biologic-level efficacy with localized delivery, avoiding systemic exposure and associated side effects. The company's business model combines a focused clinical pipeline with non-dilutive revenue through strategic partnerships, including agreements with Medline in wound care markets.
Competitive Landscape
Pro stress-test →Turn competes in the dermatology therapeutic space against established players like AbbVie (Rinvoq, Skyrizi) and GSK (Nucala) that offer systemic biologics for eczema treatment. Turn's localized delivery approach differentiates on tolerability profile, but it faces entrenched competition with proven efficacy/safety data. In wound care, partnerships with distributors like Medline position Turn as a solution provider rather than direct competitor.
Industry Context
Turn Therapeutics Inc. operates in Clinical-stage Biotechnology - Dermatology/Immunology.
Key facts
Founded: 2015 · Headquarters: Westlake Village, California · Market cap: $101.3M